Prelude Capital Management’s Lipocine LPCN Stock Holding History

Prelude Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,630	Closed	-$101K	–	1409
2026 Q1	$101K	Buy	+12,630	New	+$110K	0.01%	1053
2015 Q4	–	Sell	-329	Closed	-$66K	–	1581
2015 Q3	$66K	Buy	+329	New	+$76.1K	0.01%	966
2014 Q4	–	Sell	-4,055	Closed	-$421K	–	2038
2014 Q3	$421K	Buy	4,055 +478	+13%	+$59.4K	0.06%	432
2014 Q2	$371K	Buy	+3,577	New	+$428K	0.05%	491

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Prelude Capital Management's LPCN Position: Q2 2026 in Review

Prelude Capital Management sold out of Lipocine (LPCN) in Q2 2026, closing a stake of 12,630 shares — an estimated $101K sold.

Prelude Capital Management first reported a position in LPCN in Q2 2014 and held it in 4 quarters. The position peaked at $421K in Q3 2014. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Prelude Capital Management reported no remaining Lipocine position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 12,630 Lipocine shares in Q2 2026, an estimated $101K.
Prelude Capital Management first reported a position in Lipocine in Q2 2014 and held it in 4 quarters.
Prelude Capital Management's Lipocine position peaked at $421K in Q3 2014.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.